Human prion diseases are a set of neurodegenerative disorders caused by the accumulation of undesired folded proteins in the brain. The prevalence of such disorders has increased in recent years, resulting in increased demand for human prion disease diagnostic technologies. Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are a group of rare progressive neurodegenerative disorders characterized by long incubation periods, characteristic spongiform changes associated with neuronal loss, and a failure to induce an inflammatory response, according to the Centers for Disease Control and Prevention (CDC).
According to research published in 2016 by the National Center for Biotechnology Information (NCBI) titled “Epidemiological Characteristics of Human Prion Diseases,” human prion diseases afflict roughly 1-2 people per million worldwide each year, in both hereditary and acquired forms.
Human Prion Disease Diagnostics Market: Key Takeaways
- North America remains the largest market, with the United States as its epicenter.
- Germany, Italy, and the United Kingdom will continue to be important regions in Europe, the world’s second-largest market.
- China, Japan, South Korea, and other countries are also viable candidates.
- Throughout the projected period, sales of human prion disease diagnostic equipment will be fueled by computed tomography, cerebrospinal fluid testing, and other technologies.
According to a Fact.MR analyst, “advancements in the human diagnostics industry, together with an increase in investments in cutting-edge diagnostics solutions, are fueling market expansion.”
What are the Key Challenges Faced by Human Prion Disease Diagnostics Stakeholders
Though human prion disease diagnostics is gaining popularity, there are a few major obstacles that manufacturers must overcome. This is a relatively rare disease that affects just a small percentage of the global population. As a result, it is not a topic that receives much attention.
In addition, the emergence of COVID-19 in the previous year slowed the growth of manufacturing hubs.
As the attention moved to the emergency scenario, investments and initiatives centered on the pandemic’s emergence, negatively impacting human prion disease diagnostic equipment makers.
However, with the sector’s rapid and steady recovery, these negative effects are projected to fade, and manufacturers and suppliers should expect to encounter larger opportunities.
To remain ‘ahead’ of your competitors, Request for a Sample Copy
